Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.
ByAinvest
Friday, Jan 16, 2026 4:59 pm ET1min read
RPTX--
Repare Therapeutics' shareholders have approved the acquisition by XenoTherapeutics, a non-profit biotech company. The special resolution was approved by 99.76% of votes cast, excluding those required to be excluded under MI 61-101. Shareholders also approved advisory compensation for the company's named executive officers and the liquidation and dissolution of Repare in the event the acquisition is terminated. The acquisition is subject to court approval and other customary conditions, with a completion date expected on or about January 28, 2026.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet